%0 Journal Article
%T Facial Aging Improvement Case Study Using a Novel Combination of Retinol, Niacinamide, and Terminalia Chebula.
%A Handler M
%A Adams-Woodford A
%A Ayres P
%A Giancola G
%A Diaz I
%A Handler M
%A Adams-Woodford A
%A Ayres P
%A Giancola G
%A Diaz I
%A Handler M
%A Adams-Woodford A
%A Ayres P
%A Giancola G
%A Diaz I
%J J Drugs Dermatol
%V 21
%N 7
%D Jul 2022 1
%M 35816074
%F 1.608
%R 10.36849/JDD.6621
%X For decades, retinoids have been considered the gold standard of treatment for a variety of skin conditions.1,2 As the bioavailable form of vitamin A, retinoic acid has demonstrated the ability to reduce skin discoloration, stimulate collagen production, reduce rhytids, improve acne, and uneven skin texture.3,4 Retinoic acid is a potent drug with high bioavailability. Challenges with such a product include skin sensitivity and retinoid dermatitis.1,5 This potential irritation and discomfort may hinder patient compliance reducing visible results. The non-prescription vitamin A ingredient retinol is an effective and less irritating alternative, as it is converted into retinoic acid within the skin, causing little to no irritation when used topically. Intensive Age Refining Treatment: 0.5% pure retinol night by PCA SKIN® contains 0.5% retinol, protected and delivered into the skin with a multi-layered liposomal delivery technology. This development addresses the inherent instability of retinol,1,2,3 as well as the mitigation of irritation with the goal of enhancing patient compliance and visible results. This formulation also features niacinamide and terminalia chebula to further support the anti-aging benefits of retinol. The 12-week in vivo use of this potent, yet non-irritating retinol topical demonstrates improved patient compliance and satisfaction due to tolerability and enhanced efficacy in the improvement in overall signs of healthy skin. J Drugs Dermatol. 2022;21(7):784-788. doi:10.36849/JDD.6621.